Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
16 studies found for:    cholangiocarcinoma | United States, North Carolina
Show Display Options
Rank Status Study
1 Recruiting CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
Conditions: Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Cholangiocarcinoma of the Gallbladder;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Extrahepatic Bile Duct Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Intervention: Drug: 6,8-bis(benzylthio)octanoic acid
2 Completed
Has Results
S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma
Conditions: Extrahepatic Bile Duct Cancer;   Gallbladder Cancer
Interventions: Drug: capecitabine;   Drug: gemcitabine hydrochloride
3 Active, not recruiting
Has Results
S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct
Conditions: Extrahepatic Bile Duct Cancer;   Gallbladder Cancer
Interventions: Drug: capecitabine;   Drug: gemcitabine hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
4 Completed
Has Results
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
Conditions: Extrahepatic Bile Duct Adenocarcinoma;   Gallbladder Adenocarcinoma;   Gallbladder Adenocarcinoma With Squamous Metaplasia;   Hilar Cholangiocarcinoma;   Recurrent Extrahepatic Bile Duct Carcinoma;   Recurrent Gallbladder Carcinoma;   Undifferentiated Gallbladder Carcinoma;   Unresectable Extrahepatic Bile Duct Carcinoma;   Unresectable Gallbladder Carcinoma
Interventions: Drug: Erlotinib Hydrochloride;   Drug: Sorafenib Tosylate
5 Recruiting Quality of Life in Patients With Primary Sclerosing Cholangitis
Condition: Primary Sclerosing Cholangitis
Intervention: Other: quality of life survey
6 Recruiting Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy
Condition: Cholangiocarcinoma
Intervention: Drug: INCB054828
7 Terminated Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Condition: Hilar Cholangiocarcinoma
Interventions: Drug: Photodynamic therapy-Photofrin;   Procedure: Stenting procedure;   Drug: Chemotherapy regimen
8 Completed Biological Therapy in Treating Patients With Metastatic Cancer
Conditions: Breast Cancer;   Colorectal Cancer;   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Gastric Cancer;   Head and Neck Cancer;   Liver Cancer;   Lung Cancer;   Metastatic Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Testicular Germ Cell Tumor
Intervention: Biological: CEA RNA-pulsed DC cancer vaccine
9 Completed Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer
Conditions: Breast Cancer;   Colorectal Cancer;   Gallbladder Cancer;   Gastric Cancer;   Head and Neck Cancer;   Liver Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Testicular Germ Cell Tumor
Intervention: Biological: TRICOM-CEA(6D)
10 Active, not recruiting Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Conditions: Adult Cholangiocarcinoma;   Advanced Adult Hepatocellular Carcinoma;   BCLC Stage C Adult Hepatocellular Carcinoma;   BCLC Stage D Adult Hepatocellular Carcinoma;   Hilar Cholangiocarcinoma;   Localized Non-Resectable Adult Liver Carcinoma;   Recurrent Adult Liver Carcinoma;   Recurrent Childhood Liver Cancer;   Recurrent Extrahepatic Bile Duct Carcinoma;   Recurrent Gallbladder Carcinoma;   Stage II Gallbladder Cancer;   Stage III Childhood Hepatocellular Carcinoma;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IV Childhood Hepatocellular Carcinoma;   Stage IV Distal Bile Duct Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Carcinoma
Interventions: Drug: Capecitabine;   Drug: Fluorouracil;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Trametinib
11 Recruiting Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Conditions: Breast Cancer;   Cholangiocarcinoma;   Colorectal Cancer;   Head and Neck Neoplasms;   Lymphoma, Large-Cell, Anaplastic;   Melanoma;   Neuroendocrine Tumors;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Primary Brain Tumors;   Renal Cell Carcinoma;   Sarcomas;   Salivary Gland Cancers;   Adult Solid Tumor
Intervention: Drug: Entrectinib
12 Recruiting A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
Condition: Advanced or Metastatic Solid Tumors
Interventions: Drug: ABBV-368;   Drug: Nivolumab
13 Recruiting A Study of ABBV-181 in Participants With Advanced Solid Tumors
Condition: Advanced Solid Tumors
Intervention: Drug: ABBV-181
14 Recruiting Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Conditions: Acinar Cell Carcinoma;   Adrenal Cortex Carcinoma;   Adrenal Gland Pheochromocytoma;   Anal Canal Neuroendocrine Carcinoma;   Anal Canal Undifferentiated Carcinoma;   Appendix Mucinous Adenocarcinoma;   Bartholin Gland Transitional Cell Carcinoma;   Bladder Adenocarcinoma;   Bronchioloalveolar Carcinoma;   Cervical Adenocarcinoma;   Cholangiocarcinoma;   Chordoma;   Colorectal Squamous Cell Carcinoma;   Dermoid Cyst;   Endometrial Transitional Cell Carcinoma;   Endometrioid Adenocarcinoma;   Esophageal Neuroendocrine Carcinoma;   Esophageal Undifferentiated Carcinoma;   Extrahepatic Bile Duct Carcinoma;   Fallopian Tube Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Fibromyxoid Tumor;   Gastric Neuroendocrine Carcinoma;   Gastric Squamous Cell Carcinoma;   Giant Cell Carcinoma;   Intestinal Neuroendocrine Carcinoma;   Intrahepatic Cholangiocarcinoma;   Lung Carcinoid Tumor;   Lung Sarcomatoid Carcinoma;   Major Salivary Gland Carcinoma;   Malignant Odontogenic Neoplasm;   Malignant Peripheral Nerve Sheath Tumor;   Malignant Testicular Sex Cord-Stromal Tumor;   Metastatic Malignant Neoplasm of Unknown Primary Origin;   Mixed Mesodermal (Mullerian) Tumor;   Mucinous Adenocarcinoma;   Mucinous Cystadenocarcinoma;   Nasal Cavity Adenocarcinoma;   Nasal Cavity Carcinoma;   Nasopharyngeal Carcinoma;   Nasopharyngeal Papillary Adenocarcinoma;   Nasopharyngeal Undifferentiated Carcinoma;   Oral Cavity Carcinoma;   Oropharyngeal Undifferentiated Carcinoma;   Ovarian Adenocarcinoma;   Ovarian Germ Cell Tumor;   Ovarian Mucinous Adenocarcinoma;   Ovarian Squamous Cell Carcinoma;   Ovarian Transitional Cell Carcinoma;   Pancreatic Acinar Cell Carcinoma;   Pancreatic Neuroendocrine Carcinoma;   Paraganglioma;   Paranasal Sinus Adenocarcinoma;   Paranasal Sinus Carcinoma;   Parathyroid Gland Carcinoma;   Pituitary Gland Carcinoma;   Placental Choriocarcinoma;   Placental-Site Gestational Trophoblastic Tumor;   Primary Peritoneal High Grade Serous Adenocarcinoma;   Pseudomyxoma Peritonei;   Scrotal Squamous Cell Carcinoma;   Seminal Vesicle Adenocarcinoma;   Seminoma;   Serous Cystadenocarcinoma;   Small Intestinal Adenocarcinoma;   Small Intestinal Squamous Cell Carcinoma;   Spindle Cell Neoplasm;   Squamous Cell Carcinoma of the Penis;   Teratoma With Malignant Transformation;   Testicular Non-Seminomatous Germ Cell Tumor;   Thyroid Gland Carcinoma;   Tracheal Carcinoma;   Transitional Cell Carcinoma;   Undifferentiated Gastric Carcinoma;   Ureter Adenocarcinoma;   Ureter Squamous Cell Carcinoma;   Urethral Adenocarcinoma;   Urethral Squamous Cell Carcinoma;   Vaginal Adenocarcinoma;   Vaginal Squamous Cell Carcinoma, Not Otherwise Specified;   Vulvar Adenocarcinoma;   Vulvar Squamous Cell Carcinoma
Interventions: Procedure: Biospecimen Collection;   Biological: Ipilimumab;   Biological: Nivolumab
15 Recruiting Open-Label, Dose-Escalation Study of INCB054828 in Subjects With Advanced Malignancies
Conditions: Malignant Solid Tumour;   Carcinoma, Non-Small-Cell Lung;   Stomach Neoplasms;   Urothelial Carcinoma;   Endometrial Neoplasms;   Multiple Myeloma;   MPN;   Breast Cancer;   Cholangiocarcinoma
Interventions: Drug: INCB054828;   Drug: Gemcitabine+Cisplatin;   Drug: Pembrolizumab;   Drug: Docetaxel
16 Completed Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
Conditions: Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Liver Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium

Study has passed its completion date and status has not been verified in more than two years.